Vericel Corp (VCEL) : Stonepine Capital Management scooped up 41,052 additional shares in Vericel Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 1,417,939 shares of Vericel Corp which is valued at $4.2 Million.Vericel Corp makes up approximately 5.19% of Stonepine Capital Management’s portfolio.
Other Hedge Funds, Including , Blackrock Fund Advisors boosted its stake in VCEL in the latest quarter, The investment management firm added 20,989 additional shares and now holds a total of 55,762 shares of Vericel Corp which is valued at $163,383. Numeric Investors sold out all of its stake in VCEL during the most recent quarter. The investment firm sold 36,200 shares of VCEL which is valued $96,292.
Vericel Corp opened for trading at $2.95 and hit $3.12 on the upside on Monday, eventually ending the session at $3, with a gain of 2.39% or 0.07 points. The heightened volatility saw the trading volume jump to 1,10,435 shares. Company has a market cap of $72 M.
Many Wall Street Analysts have commented on Vericel Corp. Vericel Corp was Downgraded by BofA/Merrill to ” Neutral” on Apr 5, 2016. Needham Upgraded Vericel Corp on Mar 11, 2016 to ” Buy”, Price Target of the shares are set at $12.
Vericel Corporation (Vericel) formerly Aastrom Biosciences Inc. develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes) an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel (cultured epidermal autografts) a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA). The Company is also developing ixmyelocel-T a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The Company has two cell manufacturing facilities in Cambridge Massachusetts and Copenhagen Denmark. Vericel also operates a centralized cell manufacturing facility in Ann Arbor Michigan.